Clinical trial
Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis
NCT00244842 · Aurinia Pharmaceuticals Inc., Industry · Completed
Key facts
| NCT number | NCT00244842 |
|---|---|
| Title | Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis |
| Official title | A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients |
| Acronym | SPIRIT |
| Lead sponsor | Aurinia Pharmaceuticals Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | voclosporin, Placebo |
| Enrollment | 451 |
| Start date | Dec 1, 2004 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Oct 27, 2005 |
| Last update posted | Mar 27, 2023 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: